A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

This multi-center Phase II study evaluated lapatinib, pazopanib, and the combination in patients with relapsed HER2+ inflammatory breast cancer. In Cohort 1, 76 patients were randomized 1:1 to receive lapatinib 1,500 mg + placebo or lapatinib 1,500 mg + pazopanib 800 mg (double-blind) once daily unt...

Descripción completa

Detalles Bibliográficos
Autores principales: Cristofanilli, Massimo, Johnston, Stephen R. D., Manikhas, Alexey, Gomez, Henry L., Gladkov, Oleg, Shao, Zhimin, Safina, Sufia, Blackwell, Kimberly L., Alvarez, Ricardo H., Rubin, Stephen D., Ranganathan, Sulabha, Redhu, Suman, Trudeau, Maureen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539065/
https://www.ncbi.nlm.nih.gov/pubmed/23239151
http://dx.doi.org/10.1007/s10549-012-2369-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539065/
https://www.ncbi.nlm.nih.gov/pubmed/23239151
http://dx.doi.org/10.1007/s10549-012-2369-x

Ejemplares similares